Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Vaxart (NASDAQ:VXRT) reported positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. Norovirus is the leading cause of acute viral gastroenteritis in...

July 7, 2023

Developments

Revive oral Bucillamine flunks Phase 3 COVID-19 study

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV) reported that its Phase 3 clinical study evaluating the safety and efficacy of oral Bucillamine in patients with mild- to-moderate COVID-19 did not achieve statistical...

July 6, 2023

Developments

ASLAN posts positive Phase 2b results in atopic dermatitis

ASLAN Pharmaceuticals (NASDAQ:ASLN) reported positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis, which is often referred to as eczema...

July 6, 2023

Developments

FDA clears protocol for Acasti Phase 3 trial in aSAH

Acasti Pharma (NASDAQ:ACST) and the FDA agreed on the protocol of a Phase 3 trial of GTX-104 in patients with aneurysmal subarachnoid hemorrhage (aSAH), a rare disease with bleeding over the surface of the brain in the...

July 5, 2023

Developments

Palisade Bio completes enrollment in dose optimization study

Palisade Bio (NASDAQ:PALI) completed patient enrollment in its dose optimization study of LB1148, a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal...

July 5, 2023

Developments

Cognition, AD consortium initiate Phase 2 START study

Cognition Therapeutics (NASDAQ:CGTX) and the Alzheimer’s Clinical Trials Consortium initiated the first clinical site in the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease (AD)...

July 5, 2023

Markets

Stifel ups Black Diamond Therapeutics to buy; PT to $10 on Phase 1 data

Stifel upgraded Black Diamond Therapeutics (NASDAQ:BDTX) to “buy” from “hold” and raised its price target to $10 from $2 after the company reported initial dose escalation data demonstrating anti-tumor activity of BDTX...

June 30, 2023

Developments

RenovoRx presents positive interim Phase 3 data in pancreatic cancer

RenovoRx (NASDAQ:RNXT) presented new positive data on progression-free survival from the pivotal Phase 3 open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced...

June 29, 2023

Developments

IntraBio posts positive Phase 3 trial in Niemann-Pick disease Type C

Closely-held IntraBio reported positive topline results from a Phase 3 clinical trial, showing IB1001 significantly improved symptoms, functioning, quality of life, and cognition in pediatric and adult patients with...

June 29, 2023

Developments

PharmaJet Tropis system authorized for 2 nucleic acid vaccines

PharmaJet’s Tropis system is now the exclusive intradermal delivery system for two authorized novel COVID-19 vaccines. They include: The world’s first plasmid DNA COVID-19 vaccine for administration in humans from Zydus...

June 28, 2023

Developments

Cognition posts positive topline Phase 2 results in AD

Cognition Therapeutics (NASDAQ:CGTX) reported topline results from its Phase 2 double-blind, single-crossover SEQUEL study of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease that met its primary endpoints...

June 28, 2023

Developments

FDA clears BriaCell pivotal study in breast cancer

The FDA approved BriaCell Therapeutics’ (NASDAQ:BCTX; TSX: BCT) pivotal registrational study design for Bria-IMT in combination with a checkpoint inhibitor in advanced metastatic breast cancer, including the study...

June 27, 2023

Vaxart posts positive Phase 2 data from bivalent norovirus vaccine

Revive oral Bucillamine flunks Phase 3 COVID-19 study

ASLAN posts positive Phase 2b results in atopic dermatitis

FDA clears protocol for Acasti Phase 3 trial in aSAH

Palisade Bio completes enrollment in dose optimization study

Cognition, AD consortium initiate Phase 2 START study

Stifel ups Black Diamond Therapeutics to buy; PT to $10 on Phase 1 data

RenovoRx presents positive interim Phase 3 data in pancreatic cancer

IntraBio posts positive Phase 3 trial in Niemann-Pick disease Type C

PharmaJet Tropis system authorized for 2 nucleic acid vaccines

Cognition posts positive topline Phase 2 results in AD

FDA clears BriaCell pivotal study in breast cancer

General

More